Quva Pharma, Inc., Sugar Land, TX

Is Quva Pharma, Inc. an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Quva Pharma, Inc. in Sugar Land, TX, first registered Sep 10, 2015 and most recently registered Oct 23, 2026. FDA lists its last inspection as May 4, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 10/16/2026; FMD-145 Issued 10/19/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Sugar Land, TX
Initial registration
Sep 10, 2015
Most recent registration
Oct 23, 2026
Last inspection
May 4, 2026
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Response Letter Issued 10/16/2026; FMD-145 Issued 10/19/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as QuVa Pharma, Inc, Sugar Land, TX, a 503B facility, with 8 listed actions, including 4 Form 483s and 1 untitled letter (2019 to 2026).

Document
May 5, 2026FMD-145 letterFMD-145 Letter Issued 05/05/2026Not linked by FDA
May 4, 2026Form 483483 Issued 05/04/2026fda.gov
Jun 18, 2025Untitled letterUntitled Letter Issued 06/18/2025fda.gov
Oct 28, 2024Form 483483 Issued 10/28/2024FDA copy (archived)
Feb 1, 2023FMD-145 letterFMD-145 Letter Issued 02/01/2023Not linked by FDA
Jan 24, 2023FMD-145 letterFMD-145 Letter Issued 01/24/2023Not linked by FDA
Aug 18, 2022Form 483483 Issued 08/18/2022fda.gov
Apr 23, 2019Form 483483 Issued 04/23/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists QuVa Pharma, Inc., Sugar Land, TX (FEI number 3012053582), matched to this page by exact name, city and state. It lists 5 inspections: 1 OAI, 4 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 28, 2024Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30120535821238474
Aug 18, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30120535821177937
Apr 23, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30120535821087147
Jun 2, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30120535821012820
Feb 8, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3012053582957761

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 21 numbered observations in all, across 5 inspections ending Mar 12, 2016 to May 4, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 20, 2026 to May 4, 2026: 3 observations

Firm on the cover
QuVa Pharma, Inc., 1075 W Park One Dr Ste 100, Sugar Land, TX 77478-2576
FEI number
3012053582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, your firm failed to adequately establish procedures to prevent microbiological contamination of drug products purporting to be sterile. For example,

A. Your firm failed to adequately define and document the frequency of disinfection of a device used by technicians to pick items off the floor and place items into the trash in the ISO 7 cleanrooms. The device storage location has not been defined and documented. Currently, your technicians hang the device on the side of the <Redacted B4> used to hold drug components, utensils, drug product containers, and finished drug products.

B. On 4/20/2026, during a site walk-through of your firm's ISO 7 classified aseptic processing cleanroom, I observed a "black residue" near the <Redacted B4> of each <Redacted B4> used to hold drug components, utensils, drug product containers, and finished drug products <Redacted B4> within all ISO 7 cleanrooms. Your firm's technicians failed to adequately clean and disinfect the entire <Redacted B4> located within the ISO 7 cleanroom.

C. ...

Read the full 483 (PDF on fda.gov)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, during a review of nonconforrmance number, IR-12512 (DEV-02984) documented on 14 Nov 2024, prior to compounding Fentanyl Citrate PF 50 mcg/mL Syringe, PC 700092168448, Lot 10138352, Expiry 02/12/2025 compounding in ISO 7 Cleanroom Suite 7, ISO 5 LAFH numbered <Redacted B4> your compounding technician found on the ISO 5 LAFH grate in front of the installed HEPA filter, a brown to black foreign residue contaminate, later within an investigation identified as a "Heat Resistant 6Sealant <Redacted B4>. The sealant is applied during the HEPA filter production as an exterior coating. Potential particulates from the degradation may become an airborne contaminate affecting first air quality used during aseptic processing of sterile drug product. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Buildings used in the manufacturing, processing, packing and holding of a drug product are not maintained in a good state of repair.

Specifically, on 4/20/2026, during a site walk-through of your firm's ISO classified cleanroom, I observed paint peeling off Suite 3 ISO 8 Degowning Room wall comers and around the door frame exiting the ISO 7 Cleanroom.

exiting the ISO 7 Cleamoom.

Inspection Sep 24, 2024 to Oct 28, 2024: 4 observations

Firm on the cover
QuVa Pharma, Inc., 1075 W Park One Dr St e 100, Sugar Land, TX 77478-2576
FEI number
3012053582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, for example:

A. During a review of your firm's incident reports (!Rs) since the previous FDA inspection, your firm failed to adequately investigate the following documented events:

1. Your firm documented 10 -2024 !Rs and 19 -2023 !Rs of <Redacted B4> for ISO 5 BSC/ LAFU "Hood Cleaning contact time discrepancy" for use of your firm's disinfectant agent, <Redacted B4> less than <Redacted B4> per manufacturer specification to disinfect surfaces within your firm's ISO 5 BSC/ LAFU used in the aseptic processing of sterile drug products. Your firm's documented root cause was "Personnel Error". Your firm's documented corrective action for the root cause to prevent recurrence was to conduct employee training. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Complaint records are deficient in that they do not include the findings of the investigation.

Specifically, during a review of your firm's complaint, QuVa Complaint-0839 dated 12/28/2023, concerning the sterile finished drug product, Hydromorphone HCL PF 30 mg (1 mg/ml) 30 ml in 0.9% Sodium Chloride Solution PCA vial, NDC 70092111779, Lot <Redacted B4> Expiry 12/20/2023 (Preparation Date 9/21/2023); and Lot <Redacted B4> Expiry 11/1372023-CPreparation 8/15/2023). Your firm's customer reported the product failed internal testing and 6 total partially filled and 2 total fully filled unopened (3 partial and 1 fully filled samples from each lot) samples were returned to your QuVa Bloomsbmy , NJ location to undergo sample receiving inspection, laboratory testing using mass SQectroscopy, and investigation by QuVa Sugai· Land, TX. Your testing laborato1y reported Lot <Redacted B4> & Lot <Redacted B4> 11 samples tested positive for Sodium Chloride and only one ofthe fully intact samples (Lot <Redacted B4>) reported a Hydromorphone potency of 101.3%. No Hydromorphone potency was documented for Lot <Redacted B4> fully intact sample. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, your firm's quality unit failed to adequately implement the procedure, COR-SOP-QS-0012 fucident Reporting and Escalation Failure to adequately investigate. For example:

A. During a review of reported deviation, your firm failed to adequately investigate and implement corrections to prevent the recurrence of the following:

1. Your firm documented the following DEV-0222 02222 dated 9/18/2023, your firm reported OOS-00527 concerning a potency failure for Phenylephrine 20mg add to 250ml NS Bag, NOC/ Product Code 70092904205, Lot~<Redacted B4> concerning laboratory results for the <Redacted B4> sample of 204.1 % (Specification <Redacted B4>. Your firm's investigation reported the root cause as being compounding error. It was further reported the operator, <Redacted B4> did not realize the bag was already dosed, and consequently, dosed the bag twice". Your firm's corrective action addressed technician training; however, your firm failed to adequately investigate and assign preventive actions for the following:

AMENDMENT 1 ...

Read the full 483 (PDF on fda.gov)

Observation 4

Your fnm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, during a review of your firm's customer complaints, your firm received 15 complaints for leaking syringes, 10 ml in SWFI <Redacted B4> and 50 ml NS syringes for cracks along the syringe barrel. For example, a review ofreceived customer complaints, QuVa Complaints-0561, 0642, 0656, 0691, 0698, 0716, and 0871 repo1ted cracks potentially occmTed dming shipping/distribution yom firm's customer. Your firm's investigation failed to include internal packing process validation(s). During a review of your firm's pack-out validation reports: Winter Pack Out Shipping Validation Report, Report # COR­ENG-R-00028 dated 22 March 2022; and Summer Pack Out Shipping Validation Report, Report # COR-ENG-R-00022 dated 02 October 2021, was found to assess only the 3 ml syringe packaging configuration in the control of drug product temperature while shipping. ...

Read the full 483 (PDF on fda.gov)

Inspection Jul 11, 2022 to Aug 18, 2022: 3 observations

Firm on the cover
QuVa Pharma, Inc., 1075 W Park One Dr Ste 100, Sugar Land, TX 77478-2576
FEI number
3012053582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically, on 7/27/2022, during visual observations of your firm's <Redacted B4> -Shift Compounding Technicians gowning within the ISO 8 Anteroom, cleaning methods of the ISO 5 LAFlJ and ISO 5 BSCs, aseptic processing, and environmental monitoring sample collection methods; I observed within Cleanroom <Redacted B4> ISO 8 Anteroom, EM Technician and Compounding Technician attempt to don a sterile gown in order to gain entiy into your firm's ISO 7 Cleanroom where <Redacted B4> ISO 5 BS Cs are located used to produce the hazardous drug product, Cefazolin PF. EM Technician was observed touching the outside of the gown and touching a cart while attempting to don the sterile gown. Compounding Technician was observed failing to put on an addition pair of shoe covers after entering from a different area within controlled non-classified area of your facility to begin sterile gown donning process. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Determinations of conformance to appropriate written specifications for acceptance are deficient for drug products.

Specifically, on 7/12/2022 during a walk-through of the firm's <Redacted B4> Laboratory where samples are received from production, I observed sterile finished drug products, Methohexital Sodium l00mg/10 mL PF, Lot Numbers <Redacted B4> (Exp: 10/9/2022) and <Redacted B4> (Exp: 10/9/2022) sitting on a table at room temperature for an unspecified amount of time awaiting to be received by the <Redacted B4> laboratory. Methohexital Sodium 100mg/10 mL PF product label specifies it should be refrigerated. Your firm's Laboratory Supervisor stated due to limited space in the sample receiving area, finished drug samples are not refrigerated until after they have been checked into the lab. At that time, they are received and refrigerated. Samples undergo sterility testing using <Redacted B4>.

Observation 3

The written stability testing program is not followed.

Specifically, during a review of your BUD stability report, Dexamethasone Phosphate 6mg in 25mL NS (0.24mg/mL) in 50mL IV Bag (API) 90 Days BUD Stability Study Report, which was produced as paii of the <Redacted B4>, I found the following deficiency within the provided report used to establish the 90 day BUD for the distributed lots of drug product.

A. Your firm failed to provide a documented justification for not performing a Container Closure Integrity test at the 90 day assigned BUD for the <Redacted B4> used as the primary packaging to ensure the bag was adequate for its intended use. Container Closure Integrity test was performed only at <Redacted B4> days. There was a total of CSP Lots <Redacted B4> produced between 11/2/2020 to 11/25/2020 in which were distribu•ted to hospitals.

Inspection Apr 5, 2019 to Apr 23, 2019: 6 observations

Firm on the cover
QuVa Pharma, Inc., 1075 W Park One Dr St e 100, Sugar Land, TX 77478-2576
FEI number
3012053582
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
lJISlRICT ADDRESS AND PHONE NUMl!ER 4040 North Centr al Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Equipment for adequate control over air pressure, humidity and temperature is not provided when appropriate for the manufacture, processing, packing or holding of a drug product.

Specifically, your firm failed to adequately implement procedure, QuVa Phanna Facility Standard, COR-SOP-FM-0002, Rev. 4, concerning measuring, recording, and monitoring of conntrolled space temperature relative humidity and differential pressure. For example, your firm <Redacted B4> system <Redacted B4> failed to electronically measure, record, and transfer environmental conditions data in Cleanrooms <Redacted B4> or the dates/times 313.(Ji.0 19 @ 8:00am -3/5/2019 @8:00 am & 3/5/19@ 11 :00 pm -3/7/2019 @ 5:00 pm for Cleanrooms I -to a designated server. During these dates and times, your finn facilities management and quality unit was unaware of the condition and continued to aseptically process sterile drug products. Your firrn's <Redacted B4> failed to send notifications to the Facilities Management Department regarding the issue of missing me.asurement data.

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically,

A) On 4/5/2019, while conducting observations of the firm's compounding technician aseptically processing Heparin 30,000 units added to I 000ml 0.9% Sodium Chloride solution bag, Item 7009128108, Lot 10023176, Expiry 7/4/20 I 9, 1 observed processing supplies and drug components blocking the movement of first pass air during filling sterile to sterile product transfer, which potentially may result in cross-contamination in LAF hood <Redacted B4>

1 B) On 4/8/2019, while observing environmental sampling of Cleanroom <Redacted B4> environmental sampling technician fail to re-sanitize gloves following performing tasks in the ISO 7 area prior to placing air sampling unit in BSC <Redacted B4> where the compounding technician was aseptically process Cefazolin PF 2 gadded to l00mL NS Bag, ltem 70092101803, Lot 10023328.

Observation 3

Equipment and utensils are not cleaned and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically,

A) Your firm 's stools located in all ISO 7 Cleanrooms, used by your compounding technicians during aseptic processing, is covered with a material which cannot be adequately disinfected.

B) On 4/5/2019 during a walk-through ofyour firm 's aseptic processing areas, I observed in LAF hood <Redacted B4> HEPA grate with white and black residue, while aseptic processing Morphine PF lmg/ml 100 ml (I mg/ml) in 0.9% Sodium Chloride solution <Redacted B4>, ltem 70092151875, Lot I 0023288, Expiry 7/4/2019, Qty <Redacted B4>units. Your firm 's Senior Director of Production Operations stated compounding technicians cleaned the HEPA filter grate. He continued in stating the firm believes it was caused by sterile drug product splash during aseptic processing. No laboratory analysis was performed on the foreign material to confirm its identity.

Observation 4

Jnvestigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product.

Specifically, during review of Recall# D-0295-2019, Norepinephrine 8 mg (32 mcg/mL) added to 0.9% Sodium Chloride Injection 250 mL Bag, your firm's investigation identified the issue to be a drug component picking issue. Your firm's compounding technician aseptically admixed 250mL 5% Dextrose Injection 250 mL Bag in error. Your firm 's quality unit failed to investigate why your firm 's <Redacted B4> Testing Laboratory failed to report an unusual peak found during potency testing. l requested the lot laboratory test data, which resulted in the firm finding the presence of an unknown peak of the finished sterile drug product sample. Your firm's director ofquality reported the firm will be reopening the CAPA to further investigate this finding made during this inspection. Your firm failed to adequately investigate the unusual laboratory test results.

Observation 5

Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.

Specifically, during a walk-though of your firm's non-controlled sterile drug finjshed drug storage located at 1005 fndustrial Blvd., Sugar Land TX, I found your firm's quality unit failed to review and approve <Redacted B4> tefrigeration unit maintenance/monitoring logs since l 0/2018 used for storage of sterile non-controlled finished drug products. Your finn's quality manager stated the logs should have been reviewed and approved by the quality unit.

Observation 6

Your compounded drugs that are essentially a copy of one or more approved drugs within the meaning ofsections 503(a)(5) and 503B(d)(2).

Specifically, your compounded drug products that:

a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under Section 506E at the time of compounding, distribution, and dispensing; of

b) are not identical or nearly identical to an approved drug, but that contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

A. Phenylephrine HCL, 50mg added to 250ml 0.9% Sodium Chloride Solution Bag, Item 70092104505, Lot 10019552, Expiry 4/12/20l9.

B. Neostigmine, Img/ml 5 ml Syringe, Item 70092118944, Lot 10022441, Expiry 6/1 6/2019.

Inspection dated Mar 12, 2016 by FDA (dates on the form not read): 5 observations

Firm on the cover
QuVa Pharma, Inc., 1075 West Park One Drive Suite # 100, CODE
FEI number
3012053582
Establishment type on the cover
Sugar Land, TX 77478 Outsourcing Facility
FDA district office on the cover
FDA. 4040 North Central Expressway #300. Dallas, TX 75204.
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, Vancomycin, lot # 13350 (Date prepared: 10/13/2015, Expiration date: 11/12/2015) was determined to be Out of Specification (OOS) for endotoxin. The lot was not distributed.

Your investigation failed to include a determination of the root cause for the endotoxin failure.

In addition, the following three sterility OOS investigations and eleven potency OOS investigations have been open for more than thirty days, indicating the lack of an efficient and robust CAPA system:

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

A. Your media fill process simulations are not performed under the most stressful or challenging conditions. F or e xample, protocol REDACTED ( B)(4) entit led, “REDACTED (B)(4) Operator Media Fill Qua lification" dated 11/1 6/1 5 describes , in pa rt, that REDACTED (B)( 4). However, your firm has pr oduced lots of Oxyto cin REDACTED (B)(4) (i.e. REDACTED (B) (4), lot # 13472-0, Quantity: REDACTED (B)(4)).

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

SOP #103-06.02 entitled, "Surface Sampling Procedure" (Effective date: 5/22/14) documents, in part, that surface sampling will be performed REDACTED (B)(4). Review of monitoring records revealed that sampling was routinely performed REDACTED (B)(4) and no REDACTED (B)(4). Environmental monitoring is not done during production.

Observation 4

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.

Specifically, your SOP Document No.: SUG-SOP-SA-0001, entitled, "Sterile Compounding Area Cleaning and Disinfecting", dated 12/15/2015, states that REDACTED (B)(4) cleaning of the REDACTED (B)(4) shall be performed with a sporicidal disinfectant, REDACTED (B)(4) or equivalent; however, the cleaning records for REDACTED (B)(4) do not document that cleaning was performed. For example:

Observation 5

Procedures for the preparation of master production and control records are not described in a written procedure.

Specifically, SOP # 104-05.02 entitled, "Variance Investigation Policy" (Effective date: 7/15/15) does not include time limitations for the closure of investigations. Currently, your firm has at least 14 open investigations which were opened over 30 days ago.

Linked 483s whose text is not shown

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Quva Pharma, Inc.). That is not a finding beyond this index’s search.

The Quva Pharma, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

FDA’s 503B list also names Quva Pharma, Inc., Bloomsbury, NJ. Each is a separate listing with its own records; a similar name does not show they are the same firm.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.